Imaging Shared Resource

项目摘要-成像共享资源 影像共享资源（ISR）的主要目标是为Wistar研究所癌症中心成员提供 全面灵活的成像解决方案，从高端显微镜和小动物 图像分析服务。近年来，技术进步使人们有可能 利用定量的高分辨率成像方法来剖析细胞行为的时空方面 与恶性转化、转移性播散和治疗反应相关，ISR具有 充分准备好支持对这些领域的调查。在上一个预算周期，ISR进一步 随着新的科学领导、更多的人员和新的 仪器仪表和设施翻新。ISR继续提供基本的宽视野，直立和倒置 显微镜，以及低放大倍率和标本成像的常规应用，但也投资 在一个新的徕卡SP8X WLL白光扫描共聚焦显微镜，以补充现有的徕卡SP5 共焦。结合起来，这些系统响应了越来越多的需要，先进的显微镜使用内 癌症中心这款新仪器针对高分辨率、快速、活细胞成像进行了优化， 成功地研究动态的，细胞内机制所需的仪器，在多个 尺寸.此外，新的Leica SP8 MP 2-光子活体显微镜取代了过时的 Prairie Instruments型号，不仅能够提供单次会话，还能够在两种模式中提供深度成像支持 活体和固定模型，以及活体小鼠中转移性生长和肿瘤发生的纵向研究 模型尼康TiE倒置宽场系统也被添加到该设施中，特别适用于高度 自动成像，包括载玻片和平板的大面积拼接采集。TiE完全配置为 高内容，延时记录，并设置为连续，实时图像分析。进一步支持 在活体小鼠模型中进行的纵向成像研究，旨在询问转移进展和反应 在靶向治疗方面，ISR申请并获得了S10共享仪器资助（S10 OD021669） 购买新的Perkin Elmer IVIS SpectrumCT小动物成像系统。这一新文书 更换了较旧的IVIS 200，并以集成microCT单元的形式添加了新功能， 3D中的定量机会，用于更准确地定位和测量肿瘤负荷。高度 经验丰富的工作人员直接与用户合作获取图像，或培训用户操作设备 独立地。ISR专门支持复杂的多模式成像实验，包括FRAP， FRET和6D项目利用3D跟踪。ISR强调形象各个方面的道德实践 采集、后处理图像操作和分析。ISR的总体使命是帮助癌症患者 中心研究人员在可视化和分析的事件，启动恶性转化的目标， 改善癌症诊断和开发新的更好的治疗剂。

PROJECT SUMMARY – IMAGING SHARED RESOURCE The primary goal of the Imaging Shared Resource (ISR) is to provide Wistar Institute Cancer Center members with comprehensive and flexible imaging solutions, ranging from high-end microscopy and small animal imaging to complete image analysis services. In recent years, technological advances have made it possible to utilize quantitative, high resolution imaging approaches to dissect spatio-temporal aspects of cellular behavior related to malignant transformation, metastatic dissemination, and therapeutic response, and the ISR has amply positioned itself to support inquiries into these areas. During the last budget cycle, the ISR was further enhanced with new scientific leadership, additional personnel and a significant expansion of new instrumentation and facility renovations. The ISR continues to offer basic widefield, upright and inverted microscopy, as well as low magnification and specimen imaging for routine applications, but has also invested in a new Leica SP8X WLL white-light scanning confocal microscope to complement an existing Leica SP5 confocal. Combined, these systems respond to an increasing need for advanced microscopy usage within the Cancer Center. This new instrument is optimized for high resolution, rapid, live-cell imaging and has provided the instrumentation needed to successfully investigate dynamic, intracellular mechanisms in multiple dimensions. Additionally, a new Leica SP8 MP 2-Photon, intravital microscope has replaced an obsolete Prairie Instruments model and is capable of providing not only single session, deep imaging support in both live and fixed models, but also longitudinal studies of metastatic growth and tumorigenesis in live mouse models. A Nikon TiE inverted widefield system was also added to the facility and is especially useful for highly automated imaging including large area stitched acquisition of slides and plates. The TiE is fully configured for high-content, time-lapse recording and is set up for continuous, real-time image analysis. To further support longitudinal imaging studies in live mouse models designed to interrogate metastatic progression and response to targeted therapies, the ISR applied for, and was awarded an S10 shared instrument grant (S10 OD021669) for the purchase of a new Perkin Elmer IVIS SpectrumCT small animal imaging system. This new instrument replaced an older IVIS 200 and adds new functionality in the form of an integrated microCT unit as well as quantitative opportunities in 3D for more accurate localization and measurement of tumor burden. The highly experienced staff works directly with users to acquire their images, or trains users to operate equipment independently. The ISR specializes in supporting complex, multimodal imaging experiments including FRAP, FRET and 6D projects utilizing 3D tracking. The ISR stresses ethical practices in all aspects of image acquisition, post-process image manipulation and analysis. The overall mission of the ISR is to assist Cancer Center researchers in visualizing and analyzing events that initiate malignant transformation with the goal of improving cancer diagnosis, and the development of new, better therapeutic agents.